Compare American Tower Corp (AMT) vs Eli Lilly And Co (LLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Tower Corp vs Eli Lilly And Co — how do they compare? American Tower Corp trades at $168.92 (market cap $78.54B), while Eli Lilly And Co trades at $1,182.93 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 13.5× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| AMT | LLY | |
|---|---|---|
Market Cap | $78.54B | $1.06T |
Sector | Real Estate | Health |
52-Week High | $232.35 | $1.24K |
52-Week Low | $162.11 | $625.65 |
Enterprise Value | $122.07B | $1.10T |
Dividend Yield | 4.14% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $168.59, up 2.18% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals including a 26.81% net margin and 82.19% ROE. Recent news highlights its data center growth and sustainability initiatives, while analyst consensus remains strongly bullish with a $214.10 price target.
AMT presents a compelling long-term investment opportunity given its high profitability, dividend yield, and market leadership, though elevated debt levels and near-term technical weakness pose risks. Upside potential exists if the company continues executing on 5G and data center expansion, but investors should monitor interest rate sensitivity and competitive pressures.
Eli Lilly (LLY) trades at $1,188.58, down 2.33% over 24 hours, but maintains a strong technical bullish trend with support near $1,172. The company demonstrates exceptional fundamental strength, with 2025 revenue surging to $65.18B and net income reaching $20.64B, driven by robust demand for its obesity and diabetes drugs. Recent news highlights a $400B market cap surge over the past year and positive analyst coverage, though valuation multiples remain elevated.
Outlook remains positive given Lilly's dominance in high-growth therapeutic areas and consistent earnings beats, but risks include intense competition from Novo Nordisk and rich valuations. Wall Street consensus is strongly bullish with a $1,340 price target, suggesting 13% upside from current levels, supported by institutional confidence in long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
